Transcranial Magnetic Stimulation
0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Neuron BiopharmaSpain - Granada
2 programsrepetitive Transcranial Magnetic StimulationN/A1 trial
repetitive Transcranial Magnetic Stimulation over primary somatosensory cortexN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
Neuron Biopharmarepetitive Transcranial Magnetic Stimulation over primary somatosensory cortex
Neuron Biopharmarepetitive Transcranial Magnetic Stimulation
Clinical Trials (2)
Total enrollment: 80 patients across 2 trials
NCT06262425Neuron Biopharmarepetitive Transcranial Magnetic Stimulation over primary somatosensory cortex
rTMS Over S1 Enhance Motor Learning in Healthy People
Start: Jan 2024Est. completion: Jul 202560 patients
N/ACompleted
Transcranial Magnetic Stimulation on Somtosensory Cortex Enhances Motor Learning in People With Stroke
Start: Nov 2023Est. completion: Jan 202620 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.